FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041678084> ?p ?o ?g. }

• W2041678084 endingPage "3510" @default.
• W2041678084 startingPage "3502" @default.
• W2041678084 abstract "Fasciculin, a selective peptidic inhibitor of acetylcholinesterase, is a member of the three-fingered peptide toxin superfamily isolated from snake venoms. The availability of a crystal structure of a fasciculin 2 (Fas2)-acetylcholinesterase complex affords an opportunity to examine in detail the interaction of this toxin with its target site. To this end, we constructed a synthetic fasciculin gene with an appropriate leader peptide for expression and secretion from mammalian cells. Recombinant wild-type Fas2, expressed and amplified in Chinese hamster ovary cells, was purified to homogeneity and found to be identical in composition and biological activities to the venom-derived toxin. Sixteen mutations at positions where the crystal structure of the complex indicates a significant interfacial contact point or determinant of conformation were generated. Two mutants of loop I, T8A/T9A and R11Q, ten mutants of the longest loop II, R24T, K25L, R27W, R28D, H29D, ΔPro30, P31R, K32G, M33A, and V34A/L35A, and two mutants of loop III, D45K and K51S, were expressed transiently in human embryonic kidney cells. Inhibitory potencies of the Fas2 mutants toward mouse AChE were established, based on titration of the mutants with a polyclonal anti-Fas2 serum. The Arg27, Pro30, and Pro31 mutants each lost two or more orders of magnitude in Fas2 activity, suggesting that this subset of three residues, at the tip of loop II, dominates the loop conformation and interaction of Fas2 with the enzyme. The Arg24, Lys32, and Met33 mutants lost about one order of magnitude, suggesting that these residues make moderate contributions to the strength of the complex, whereas the Lys25, Arg28, Val34-Leu35, Asp45, and Lys51 mutants appeared as active as Fas2. The Thr8-Thr9, Arg11, and His29 mutants showed greater ratios of inhibitory activity to immunochemical titer than Fas2. This may reflect immunodominant determinants in these regions or intramolecular rearrangements in conformation that enhance the interaction. Of the many Fas2 residues that lie at the interface with acetylcholinesterase, only a few appear to provide substantial energetic contributions to the high affinity of the complex. Fasciculin, a selective peptidic inhibitor of acetylcholinesterase, is a member of the three-fingered peptide toxin superfamily isolated from snake venoms. The availability of a crystal structure of a fasciculin 2 (Fas2)-acetylcholinesterase complex affords an opportunity to examine in detail the interaction of this toxin with its target site. To this end, we constructed a synthetic fasciculin gene with an appropriate leader peptide for expression and secretion from mammalian cells. Recombinant wild-type Fas2, expressed and amplified in Chinese hamster ovary cells, was purified to homogeneity and found to be identical in composition and biological activities to the venom-derived toxin. Sixteen mutations at positions where the crystal structure of the complex indicates a significant interfacial contact point or determinant of conformation were generated. Two mutants of loop I, T8A/T9A and R11Q, ten mutants of the longest loop II, R24T, K25L, R27W, R28D, H29D, ΔPro30, P31R, K32G, M33A, and V34A/L35A, and two mutants of loop III, D45K and K51S, were expressed transiently in human embryonic kidney cells. Inhibitory potencies of the Fas2 mutants toward mouse AChE were established, based on titration of the mutants with a polyclonal anti-Fas2 serum. The Arg27, Pro30, and Pro31 mutants each lost two or more orders of magnitude in Fas2 activity, suggesting that this subset of three residues, at the tip of loop II, dominates the loop conformation and interaction of Fas2 with the enzyme. The Arg24, Lys32, and Met33 mutants lost about one order of magnitude, suggesting that these residues make moderate contributions to the strength of the complex, whereas the Lys25, Arg28, Val34-Leu35, Asp45, and Lys51 mutants appeared as active as Fas2. The Thr8-Thr9, Arg11, and His29 mutants showed greater ratios of inhibitory activity to immunochemical titer than Fas2. This may reflect immunodominant determinants in these regions or intramolecular rearrangements in conformation that enhance the interaction. Of the many Fas2 residues that lie at the interface with acetylcholinesterase, only a few appear to provide substantial energetic contributions to the high affinity of the complex." @default.
• W2041678084 created "2016-06-24" @default.
• W2041678084 creator A5004460355 @default.
• W2041678084 creator A5007252463 @default.
• W2041678084 creator A5019691111 @default.
• W2041678084 creator A5030576537 @default.
• W2041678084 creator A5054200641 @default.
• W2041678084 creator A5066598677 @default.
• W2041678084 creator A5082332482 @default.
• W2041678084 creator A5085707862 @default.
• W2041678084 date "1997-02-01" @default.
• W2041678084 modified "2023-09-30" @default.
• W2041678084 title "Expression and Activity of Mutants of Fasciculin, a Peptidic Acetylcholinesterase Inhibitor from Mamba Venom" @default.
• W2041678084 cites W1492287582 @default.
• W2041678084 cites W1493227437 @default.
• W2041678084 cites W1511313960 @default.
• W2041678084 cites W1513607518 @default.
• W2041678084 cites W1526151739 @default.
• W2041678084 cites W1536459857 @default.
• W2041678084 cites W1567842182 @default.
• W2041678084 cites W1569916771 @default.
• W2041678084 cites W1577601626 @default.
• W2041678084 cites W1587234113 @default.
• W2041678084 cites W1965773604 @default.
• W2041678084 cites W1968114671 @default.
• W2041678084 cites W1971021800 @default.
• W2041678084 cites W1971048984 @default.
• W2041678084 cites W1972719099 @default.
• W2041678084 cites W1976517254 @default.
• W2041678084 cites W1981076254 @default.
• W2041678084 cites W1983041559 @default.
• W2041678084 cites W1986865537 @default.
• W2041678084 cites W1990280069 @default.
• W2041678084 cites W1997803213 @default.
• W2041678084 cites W2006186836 @default.
• W2041678084 cites W2011000826 @default.
• W2041678084 cites W2011852440 @default.
• W2041678084 cites W2016996525 @default.
• W2041678084 cites W2018414456 @default.
• W2041678084 cites W2021329870 @default.
• W2041678084 cites W2021475144 @default.
• W2041678084 cites W2027122153 @default.
• W2041678084 cites W2036141180 @default.
• W2041678084 cites W2043116166 @default.
• W2041678084 cites W2051184695 @default.
• W2041678084 cites W2051679721 @default.
• W2041678084 cites W2058185609 @default.
• W2041678084 cites W2058527555 @default.
• W2041678084 cites W2063764057 @default.
• W2041678084 cites W2066224900 @default.
• W2041678084 cites W2066537699 @default.
• W2041678084 cites W2066833306 @default.
• W2041678084 cites W2069294211 @default.
• W2041678084 cites W2085958374 @default.
• W2041678084 cites W2089015588 @default.
• W2041678084 cites W2089840974 @default.
• W2041678084 cites W2091350710 @default.
• W2041678084 cites W2091353481 @default.
• W2041678084 cites W2091512475 @default.
• W2041678084 cites W2100837269 @default.
• W2041678084 cites W2118173900 @default.
• W2041678084 cites W2121140853 @default.
• W2041678084 cites W2122995887 @default.
• W2041678084 cites W2131307163 @default.
• W2041678084 cites W2135241467 @default.
• W2041678084 cites W2135602324 @default.
• W2041678084 cites W2136220160 @default.
• W2041678084 cites W2140642212 @default.
• W2041678084 cites W2155450479 @default.
• W2041678084 cites W2189084452 @default.
• W2041678084 cites W2888511473 @default.
• W2041678084 cites W4231569762 @default.
• W2041678084 cites W4240808165 @default.
• W2041678084 cites W44426163 @default.
• W2041678084 doi "https://doi.org/10.1074/jbc.272.6.3502" @default.
• W2041678084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9013597" @default.
• W2041678084 hasPublicationYear "1997" @default.
• W2041678084 type Work @default.
• W2041678084 sameAs 2041678084 @default.
• W2041678084 citedByCount "42" @default.
• W2041678084 countsByYear W20416780842012 @default.
• W2041678084 countsByYear W20416780842013 @default.
• W2041678084 countsByYear W20416780842016 @default.
• W2041678084 countsByYear W20416780842017 @default.
• W2041678084 countsByYear W20416780842019 @default.
• W2041678084 countsByYear W20416780842020 @default.
• W2041678084 crossrefType "journal-article" @default.
• W2041678084 hasAuthorship W2041678084A5004460355 @default.
• W2041678084 hasAuthorship W2041678084A5007252463 @default.
• W2041678084 hasAuthorship W2041678084A5019691111 @default.
• W2041678084 hasAuthorship W2041678084A5030576537 @default.
• W2041678084 hasAuthorship W2041678084A5054200641 @default.
• W2041678084 hasAuthorship W2041678084A5066598677 @default.
• W2041678084 hasAuthorship W2041678084A5082332482 @default.
• W2041678084 hasAuthorship W2041678084A5085707862 @default.
• W2041678084 hasBestOaLocation W20416780841 @default.
• W2041678084 hasConcept C104317684 @default.
• W2041678084 hasConcept C143065580 @default.

• next